Quarterly Activities Report and 4C Quarterly Cash Flow Report

ASX Announcements

Patrys has today released its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the quarter ended 30 September2024.

Highlights from this period include:

  • Specification testing of drug product from GMP production run of PAT-DX1 completed;
  • Based on results of specification testing, Patrys to focus internal development efforts on PAT-DX3 and seek partnering or licensing opportunities for PAT-DX1;
  • Cash and short‑term investment balance of $1.3 million on 30 September 2024, with an R&D refund of $1.3 million expected in the current quarter

Read today’s ASX release here.

Menu